Mediomics

Mediomics is a private, commercial-stage diagnostics company that has developed a suite of patented assay platforms based on DNA-based detection and fluorescence signaling. Its core technologies, Bridge-It® and PINCER®, enable highly sensitive, homogenous assays for targets like small molecules, proteins, and pathogens, primarily serving the research and pharmaceutical development markets. The company generates revenue through the sale of assay kits in various formats (e.g., 96-well, 384-well) directly to labs and pharma companies. While established in its niche, its growth is tied to expanding its assay menu and potentially transitioning platforms into clinical diagnostic applications.

Patented DNA-based proximity assays: Bridge-It® (protein-DNA interaction based) and PINCER® (DNA hybridization based) platforms utilizing FRET and Time-Resolved FRET (TRF) for homogeneous, sensitive detection of biomolecules.

Mediomics competes in the crowded life science research tools and assay kits market, dominated by global giants like Thermo Fisher, Abcam, and Merck. It differentiates through its patented, homogenous FRET/TRF-based assay designs, competing against other specialty assay providers and established technologies like ELISA, AlphaLISA, and HTRF. Its niche is researchers seeking sensitive, mix-and-read assays for specific challenging targets.